07 Februari 2022
Louis M. Staudt, National Cancer Institute, Bethesda, U.S.A.
Rational development of targeted therapies for genetic subtypes of aggressive lymphoma
Host: Ivo Touw, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
|
14 February 2022
Delfim Duarte, i3S, Porto, Portugal
Microenvironment and iron in acute myeloid leukemia
Host: Emma de Pater, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
|
21 Februari 2022
Dan Landau, Weill Cornell Medical College/ New York Genome Center, New York, U.S.A.
Charting clonal hematopoietic differentiation topologies with single-cell multi-omics
Host: Mathijs Sanders, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
|
28 Februari 2022
Charles Mullighan, St. Jude Comprehensive Cancer Center, Memphis, U.S.A.
Lineage ambiguous leukemia
Host: Ruud Delwel, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
|
07 March 2022
Stuart H. Orkin, Harvard Medical School/ HHMI, Boston, U.S.A.
Reactivation of fetal hemoglobin for therapy of hemoglobin disorders
Host: Peter Valk, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
|
14 March 2022
Peter van Galen, Brigham and Women’s Hospital/ Harvard Medical School/ Broad Institute, Boston, U.S.A.
Tracing leukemia evolution and immune cell interactions using single-cell multi-omics
Host: Marc Raaijmakers, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
|
21 March 2022
Heiko Bruns, University Hospital Erlangen, Erlangen, Germany
Function and significance of tumor-associated macrophages in lymphoma
Host: Tom Cupedo, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
|
28 March 2022
Peter Campbell, Wellcome Sanger Institute, Hinxton, U.K.
Somatic mutations in normal tissues
Host: Mathijs Sanders, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
|
04 April 2022
Lisa Russell, Newcastle University, Newcastle upon Tyne, U.K.
Super-enhancer activation of proto-oncogenes in acute lymphoblastic leukaemia: from discovery to treatment
Host: Ruud Delwel, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
|
11 April 2022
Cécile Denis, INSERM, Le Kremlin-Bicetre, France
New developments in von Willebrand factor research
Host: Frank Leebeek, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
|
25 April 2022
Wilbur Lam, Emory University School of Medicine and Georgia Institute of Technology, Atlanta, U.S.A.
Development and clinical translation of engineered microsystems in hematology
Host: Ruben Bierings, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
|
02 May 2022
John W. Weisel, University of Pennsylvania, Philadephia, U.S.A.
Mechanisms of blood clot contraction and its significance for hemostasis and thrombosis
Host: Moniek de Maat, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
|
09 May 2022
Mihai Netea, Radboud University Medical Center, Nijmegen, The Netherlands
Trained immunity: a memory for innate host defense
Host: Marc Raaijmakers, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
|
16 May 2022
Jolanta Grembecka, University of Michigan, Ann Arbor, U.S.A.
Targeted inhibition of epigenetic modifiers in leukemia
Host: Ruud Delwel, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
|
23 May 2022
Jens Lohr, Dana-Farber Cancer Institute, Boston, U.S.A.
Promiscuous lineage identity and clinical implications in patients with multiple myeloma
Host: Tom Cupedo, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
|
30 May 2022
Siddhartha Jaiswal, Stanford University School of Medicine, Stanford, U.S.A.
Clonal hematopoiesis in human aging and disease
Host: Peter Valk, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
|
20 June 2022
Roni Shouval, Memorial Sloan Kettering Cancer Center, New York, U.S.A.
Hallmarks of response and toxicity to CAR T-cell therapy
Host: Emma de Pater, Erasmus MC Cancer Institute, Rotterdam, The Netherlands |
27 June 2022
Ivo Touw, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
Molecular pathogenesis of congenital neutropenia
Host: Marc Raaijmakers, Erasmus MC Cancer Institute, Rotterdam, The Netherlands |
